Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Toxicol Lett. 2010 Apr 13;196(2):110–116. doi: 10.1016/j.toxlet.2010.04.005

Fig. 2. PCB-153 treatments decreased cyclin D1 protein levels.

Fig. 2

MCF-10A cells were treated with 0–15 µM of (A) PCB-153 and (B) PCB-3 for 4 h, and harvested for immunoblotting analysis of cyclin D1 protein levels. Blots were reprobed with antibodies to cyclin A and actin. (C) Cyclin D1 fold-change was calculated first by normalizing to actin in individual samples and then relative to untreated control. Asterisks represent statistical significance compared to untreated control; n=3, p < 0.05. (D) Total cellular RNA was extracted at the end of 4 h of PCB-153 treatments, and cyclin D1 mRNA levels were measured using a quantitative RT-PCR assay; 18S rRNA levels were used as control for the assay. ANOVA followed by Tukey’s post hoc test were used to assess statistical significance of results. Asterisks represent significant difference between control and treated samples (n=3, p < 0.05).